Drug Profile
Research programme: HIV therapeutics - Calimmune
Alternative Names: CAL X; CAL-21; CAl-XLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Calimmune
- Class Cell therapies; Gene therapies
- Mechanism of Action CCR5 receptor antagonists; Gene transference; HIV fusion inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for HIV infections in USA (Parenteral)
- 28 Oct 2018 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
- 14 Oct 2016 Preclinical development is ongoing USA (Calimmune pipeline, October 2016)